Edgar Filing: SHEFFIELD PHARMACEUTICALS INC - Form 8-K

SHEFFIELD PHARMACEUTICALS INC

Form 8-K August 14, 2002

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2002

COMMISSION FILE NUMBER 1-12584

DELAWARE

SHEFFIELD PHARMACEUTICALS, INC. (State of other jurisdiction of incorporation or organization)

SHEFFIELD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

13-3 (I.R.S. E Identific

14528 South Outer Forty Road, Suite 205, St. Louis, Missouri 63017 ______ (Zip Code) (Address of principal executive officers)

Registrant's telephone number, including area code (314) 579-9899

Not Applicable

(Former name or former address, if changed since last report)

ITEM 9. REGULATION FD DISCLOSURE

Sheffield Pharmaceuticals, Inc. (the "Company"), a Delaware corporation, is furnishing under Item 9 of this Current Report on Form 8-K the information included as Exhibit 99.1 to this report. Exhibit 99.1 includes a certification signed by the Company's Chief Executive Officer and Chief Financial Officer as required pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in connection with the Quarterly Report on Form 10-Q for the period ending June 30, 2002.

Note: The information in this report (including Exhibit 99.1) is furnished under Item 9 pursuant to 18 U.S.C. Section 1350 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number

Description

Edgar Filing: SHEFFIELD PHARMACEUTICALS INC - Form 8-K

99.1

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: August 14, 2002 By: /s/ Thomas M. Fitzgerald

Thomas M. Fitzgerald

President and Chief Executive Officer

By: /s/ Scott A. Hoffmann

Scott A. Hoffmann

Vice President and Chief Financial Officer